Top Markets
#1 0G 0G +24.46%
#2 SAFEcoin SAFEcoin +21.99%
#3 Zora Zora +20.33%
#4 Axelar Axelar +19.88%
#5 Full Moon Full Moon +18.98%
#6 AI XOVIA AI XOVIA +17.52%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.60%
#8 Cysic Cysic +16.30%
#9 VVS Finance VVS Finance +15.88%
#10 Apertum Apertum +13.84%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV
Rank in Stocks #12869
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm... Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Share Price
$11.09
Last synced: 2026-08-28
Market Cap
$542.19M
Change (1 day)
-7.12%
Change (1 year)
252.06%
Country
US
Trade Artiva Biotherapeutics, Inc. (ARTV)

Category

Healthcare
P/E ratio for Artiva Biotherapeutics, Inc. (ARTV)
P/E ratio as of 2026 TTM: 0
According to Artiva Biotherapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Artiva Biotherapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.